{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":28,"n_cols":5,"rows_kept":28,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[16,2,16,3],[17,2,17,3],[20,2,20,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910484964103321"]
[null,null,"Titolo",null,"Endoscopic Ultrasound Management of Pancreatic Lesions : From Diagnosis to Therapy / / edited by Antonio Facciorusso, Nicola Muscatiello"]
[null,null,"Pubbl/distr/stampa",null,"Cham : , : Springer International Publishing : , : Imprint : Springer, , 2021"]
[null,null,"ISBN",null,"3-030-71937-5"]
[null,null,"Edizione",null,"[1st ed. 2021.]"]
[null,null,"Descrizione fisica",null,"1 online resource (235 pages)"]
[null,null,"Collana",null,"Medicine Series"]
[null,null,"Disciplina",null,"616.3707543"]
[null,null,"Soggetti",null,"Gastroenterology"]
[{"$nulls":4},"Oncology"]
[{"$nulls":4},"Cancer - Treatment"]
[{"$nulls":4},"Radiology"]
[{"$nulls":4},"Cancer Therapy"]
[{"$nulls":4},"Malalties del pàncrees"]
[{"$nulls":4},"Endoscòpia"]
[{"$nulls":4},"Llibres electrònics"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references."]
[null,null,"Nota di contenuto",null,"Intro -- Foreword -- Contents -- 1: Overview of Pancreatic Masses and Cystic Lesions -- 1.1  Introduction -- 1.2  Epidemiological Aspects -- 1.3  Clinical Presentation -- 1.3.1  Pain -- 1.3.2  Jaundice -- 1.3.3  Weight Loss -- 1.3.4  Diabetes -- 1.3.5  Nausea and Vomiting -- 1.3.6  Signs of Malignant Transformation of Cystic Pancreatic Neoplasms -- 1.4  Genetic Mutations and Laboratory Markers -- 1.5  Imaging: What the Clinician Should Know? -- 1.5.1  Transabdominal Ultrasound (US) -- 1.5.2  Computed Tomography (CT) -- 1.5.3  Endoscopic Ultrasound and Tissue Acquisition -- 1.5.4  MRI with MR Cholangiopancreatography (MRCP) -- 1.6  Treatment and Follow-Up of Patients with Solid and Cystic Lesions of the Pancreas -- 1.7  Conclusions -- References -- 2: Overview on Inflammatory Pancreatic Fluid Collection -- 2.1  Introduction -- 2.1.1  APFCs -- 2.1.2  ANCs -- 2.1.3  Pancreatic Pseudocysts -- 2.1.4  WONs -- 2.2  Conclusions -- References -- 3: Contrast-Enhanced Endoscopic Ultrasound and Endoscopic Ultrasound Elastography -- 3.1  Introduction -- 3.2  Contrast-Enhanced Harmonic Endoscopic Ultrasound (CH-EUS) -- 3.2.1  "]
[{"$nulls":4},"CH-EUS: How to Do It? -- 3.2.2  CH-EUS Features of Solid Pancreatic Masses -- 3.2.2.1  Pancreatic Intraepithelial Neoplasia (PanIN) -- 3.2.2.2  Pancreatic Adenocarcinoma -- 3.2.2.3  Neuroendocrine Tumor (NET) -- 3.2.2.4  Solid Pseudopapillary Tumor (SPN) -- 3.2.2.5  Metastases -- 3.2.2.6  Acute Pancreatitis -- 3.2.2.7  Chronic Pancreatitis -- 3.2.2.8  Autoimmune Pancreatitis -- 3.2.2.9  Lymph Nodes -- 3.2.2.10  Lymphoma -- 3.2.2.11  Pancreatoblastoma -- 3.2.2.12  Schwannoma -- 3.2.2.13  Lipoma -- 3.2.2.14  Perivascular Epithelioid Cell Tumor (PEComa) -- 3.2.3  CH-EUS Features of Cystic Pancreatic Masses -- 3.2.3.1  Simple Pancreatic Cysts and Pseudocysts -- 3.2.3.2  Intraductal Papillary Neoplasms (IPMN)."]
[{"$nulls":4},"3.2.3.3  Mucinous Cystic Neoplasms (Cystadenoma and Cystadenocarcinoma) -- 3.2.3.4  Serous Cystadenoma -- 3.2.4  CH-EUS-Guided Tissue Sampling -- 3.3  Endoscopic Ultrasound Elastography (EUS-E) -- 3.3.1  EUS-E: How to Do It? -- 3.3.2  EUS-E Features of Solid Pancreatic Masses -- 3.3.2.1  Pancreatic Adenocarcinoma -- 3.3.2.2  Neuroendocrine Tumor -- 3.3.2.3  Solid Pseudopapillary Tumor -- 3.3.2.4  Metastases -- 3.3.2.5  Acute Pancreatitis -- 3.3.2.6  Chronic Pancreatitis -- 3.3.2.7  Autoimmune Pancreatitis -- 3.3.2.8  Lymph Nodes -- 3.3.3  EUS-E Features of Cystic Pancreatic Masses -- 3.3.4  EUS-E-Guided Tissue Sampling -- 3.4  Conclusion -- References -- 4: Endoscopic Ultrasound-Guided Tissue Acquisition of Solid Pancreatic Lesions -- 4.1  Introduction -- 4.2  The \"Standard\" Technique for EUS-TA -- 4.3  How to Improve the EUS-TA Performance in Solid Pancreatic Lesions? -- 4.3.1  The Fanning Technique -- 4.3.2  Suction or Not -- 4.3.3  FNB vs. FNA -- 4.3.4  Needle Diameter -- 4.3.5  ROSE or MOSE? -- 4.3.6  Ancillary Techniques -- 4.3.7  Reducing Adverse Events -- 4.4  Conclusion -- References -- 5: Evidence-Based Assessment of Diagnostic Performance of Currently Available Needles and Techniques for EUS-Guided Tissue Acquisition -- 5.1  Introduction -- 5.2  EUS-FNA -- 5.2.1  Needle Size -- 5.2.2  Suction -- 5.2.3  Stylet -- 5.2.4  ROSE -- 5.2.5  Fanning Technique -- 5.3  EUS-FNB -- 5.3.1  General Concepts -- 5.3.2  Comparative Effectiveness of Different FNB Needles -- 5.4  Pancreatic Cystic Lesions -- 5.5  Confocal Laser Endomicroscopy -- 5.6  Conclusions -- References -- 6: Role of EUS Sampling in Pancreatic Cystic Lesions -- 6.1  Introduction -- 6.2  Cytology of Cystic Fluid -- 6.3  Amylase -- 6.4  CEA -- 6.5  Glucose -- 6.6  Molecular Markers -- 6.7  Other Biomarkers -- 6.8  Conclusion -- References."]
[{"$nulls":4},"7: Endoscopic Ultrasound-Guided Drainage of Pancreatic Fluid Collections -- 7.1  Background -- 7.2  Indications of Drainage -- 7.3  Evaluation for Drainage -- 7.4  Equipment -- 7.4.1  Echoendoscope -- 7.4.2  Stents -- 7.4.3  Accessories -- 7.5  Technique -- 7.5.1  Drainage of Pseudocyst -- 7.5.2  Drainage of WOPN -- 7.6  Complications -- 7.7  Summary and Conclusion -- References -- 8: EUS-Guided Pancreatic Duct Drainage -- 8.1  Indications -- 8.1.1  Clinical Manifestations -- 8.1.2  Underlying Diagnoses -- 8.1.3  Underlying Anatomy of the Pancreatic Duct -- 8.2  Contraindications -- 8.2.1  Absolute -- 8.2.2  Relative -- 8.3  Preparation -- 8.4  Equipment and Devices -- 8.4.1  Equipment -- 8.4.2  Devices -- 8.5  Techniques -- 8.5.1  Rendezvous Pancreatic Duct Drainage -- 8.5.2  Antegrade (Transluminal) Pancreatic Duct Drainage -- 8.6  Stent Placement -- 8.7  Post-Procedure -- 8.8  Adverse Events -- 8.9  Follow-Up -- 8.10  Conclusion -- References -- 9: Lumen-Apposing Metal Stents: Innovation in the Management of Pancreatic Fluid Collections -- 9.1  Pancreatic Fluid Collections -- 9.1.1  History and Paradigm Change -- 9.2  Indications -- 9.2.1  Technique -- 9.2.2  Available Devices -- 9.3  Repeated Interventions and Necrosectomy -- 9.4  Adverse Events -- "]
[{"$nulls":4},"9.4.1  Procedure Adverse Events -- 9.4.2  Delayed Adverse Events -- 9.4.3  Efficacy and Economic Considerations -- 9.5  The Future -- References -- 10: Endoscopic Pancreatic Necrosectomy -- References -- 11: Role of Endoscopic Ultrasound in Pancreatic Cancer Screening -- 11.1  Introduction -- 11.2  Risk Factors for Pancreatic Cancer -- 11.3  Pancreatic Screening Tools -- 11.4  Diagnostic Imaging Modalities for Pancreatic Cancer Screening -- 11.5  Screening and EUS -- 11.5.1  EUS in Patients with a Family History of Pancreatic Cancer."]
[{"$nulls":4},"11.5.2  EUS in Pancreatic Cancer Associated with Inherited Cancer Syndrome (Mutation Carriers) -- 11.5.3  EUS in IPMN -- References -- 12: Endoscopic Ultrasound in Pancreatic Cancer Staging -- 12.1  EUS for Tumor Size Measurement -- 12.2  EUS Detection for Vascular Invasion -- 12.3  EUS for Lymph Node Detection -- 12.4  EUS-FNA -- 12.5  Peritoneal Tumor Dissemination or Malignant Ascites -- 12.6  Celiac Ganglia Metastasis Diagnosis -- 12.7  EUS-FNA in PC After Neoadjuvant Therapy -- 12.8  Limitations -- 12.9  Conclusion -- References -- 13: Endoscopic Ultrasound-Guided Fiducial Marker Placement for Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer -- 13.1  Introduction -- 13.2  Role of Fiducial Placement in SBRT for Pancreatic Lesions -- 13.3  Methods of Fiducial Placement -- 13.4  Types of Fiducials for SBRT -- 13.5  Methods of Loading the Fiducial Needle -- 13.6  Optimal Location to Place Fiducials for SBRT -- 13.7  Technical Outcomes of Fiducial Insertion in Pancreatic Lesions -- 13.8  Complications of Fiducial Insertion -- 13.9  Conclusion -- References -- 14: Endoscopic Ultrasound-Guided Therapies for Solid Pancreatic Tumors -- 14.1  Introduction -- 14.2  EUS-Guided Direct-Mode Ablation -- 14.2.1  EUS-Guided Radiofrequency Ablation -- 14.2.2  EUS-Guided Laser Ablation -- 14.2.3  EUS-Guided Cryotherm Ablation -- 14.2.4  EUS-Guided Ethanol Ablation -- 14.3  Local Ablation and Immunomodulation -- 14.4  EUS-Guided Indirect Mode Ablation -- 14.5  Conclusions -- References -- 15: Endoscopic Ultrasound-Guided Pancreatic Cysts Ablation -- 15.1  Introduction -- 15.2  Technique -- 15.3  Chemotherapy and Ethanol -- 15.4  Radiofrequency Ablation -- 15.5  Available Data -- 15.6  Conclusions -- References -- 16: Celiac Plexus Blockade/Neurolysis -- 16.1  Introduction -- 16.2  Relevant Anatomy -- 16.3  Technique."]
[{"$nulls":4},"16.3.1  EUS-Guided Celiac Plexus Injection -- 16.3.2  EUS-Guided Celiac Ganglia Injection -- 16.3.3  EUS-Guided Broad Plexus Injection -- 16.4  Efficacy of EUS-Guided Celiac Neurolysis -- 16.4.1  Overall Efficacy -- 16.4.2  Plexus vs. Ganglia Injection -- 16.4.3  Plexus vs. Broad Plexus Neurolysis -- 16.4.4  Bilateral vs. Unilateral Injection -- 16.4.5  Volume of Injectate -- 16.4.6  Early Neurolysis -- 16.5  Efficacy of EUS-Guided Celiac Blockade -- 16.6  Adverse Events of Celiac Blockade/Neurolysis -- 16.7  Conclusion -- References -- 17: Interventional Endoscopic Ultrasound in Patients on Antithrombotic Therapy -- 17.1  Introduction -- 17.2  Risk of Bleeding in Patients on Antithrombotic Therapy: A Review of the Literature -- 17.3  Management of Antithrombotic Agents -- References -- 18: Sedation for Endoscopic Ultrasound -- 18.1  Introduction -- 18.2  Benzodiazepine -- 18.3  Opioid Analgesics -- 18.4  α2 Adrenergic Receptor Agonist -- 18.5  Propofol -- 18.6  Combination of Sedative Agents -- 18.7  Conclusion -- References -- 19: Quality Measures in Endoscopic Ultrasound -- 19.1  Introduction -- 19.2  Before Endoscopy -- 19.3  During Endoscopy -- 19.4  After Endoscopy -- References -- 20: Conclusive Remarks and New Perspectives -- 20.1  General Concepts -- 20.2  EUS-Guided Tissue Sampling -- 20.3  EUS-Guided Drainage of PFCs -- 20.4  Therapeutic Role of EUS in Pancreatic Cancer Patients -- 20.5  New Perspectives -- References."]
[null,null,null,"Sommario/riassunto","This book provides a comprehensive and up-to-date overview of current endoscopic ultrasound use in all aspects of pancreatology, from diagnosis to therapy, i.e., from tissue acquisition, with standard fine-needle aspiration and the newer biopsy needles, to less invasive techniques such as contrast-enhanced ultrasound and elastography. It also covers novel therapeutic strategies, with a particular focus on ablative treatments and lumen-apposing stents, and describes techniques developed by the editors, in particular combined celiac plexus neurolysis with pancreatic tumor ethanol ablation and elastography-guided fine-needle aspiration. All topics are developed by pursuing an evidence-based approach and several recent meta-analyses, the majority of which were published by the authors. Due to several recent advances in the field, endoscopic ultrasound has taken on a pivotal role in the diagnosis, staging, and treatment of pancreatic lesions; as such, the present volume offers an invaluable tool for staying abreast of the state-of-the-art in this field."]